Compare RHI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | ADPT |
|---|---|---|
| Founded | 1948 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.5B |
| IPO Year | 1994 | 2019 |
| Metric | RHI | ADPT |
|---|---|---|
| Price | $41.90 | $29.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $39.56 | $32.57 |
| AVG Volume (30 Days) | 2.0M | ★ 2.0M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.62% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $5,378,506,000.00 | $276,976,000.00 |
| Revenue This Year | N/A | $10.85 |
| Revenue Next Year | $3.95 | $21.60 |
| P/E Ratio | $46.59 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $21.83 | $12.00 |
| 52 Week High | $47.14 | $32.21 |
| Indicator | RHI | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.08 | 58.55 |
| Support Level | $35.08 | $24.02 |
| Resistance Level | $42.25 | $29.92 |
| Average True Range (ATR) | 1.58 | 1.83 |
| MACD | -0.19 | 0.35 |
| Stochastic Oscillator | 17.03 | 60.05 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.